Antipsychotic discontinuation
Antipsychotic discontinuation has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, May 1, 2026: “Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study”.
1 paper studies it1 findingUpdated
See all 1 papers on antipsychotic discontinuation
At a glance
The findings reach people, from one lab or study. 1 lab in 2 countries.
“Estimated risks for stroke, pneumonia, and all-cause mortality were similar between strategies.”
- 1 lab in 2 countries
- Funders: Monash University and 2 more
- 1 of 1 finding with company ties
- Humans1
What did studies of antipsychotic discontinuation find?
1Studies of antipsychotic discontinuation measured 1 outcome; the most studied are mortality (1 study).
Mortality
no changein humans1
1 study
Mortality
no changein humans1
Antipsychotic discontinuation was not clearly linked with mortality in people living with dementia after 12 weeks of antipsychotic treatment (similar between strategies).
“Estimated risks for stroke, pneumonia, and all-cause mortality were similar between strategies.”
Humansin people living with dementia after 12 weeks of antipsychotic treatment24 monthsn = 24,822
The lancet. Healthy longevity